PMHS Polomar Health Services, Inc.
Company Updates ·
Alexandra Peterson and Gabrielle Toledano resigned effective October 14, 2026, and the board reduced its size from five to three. The board has not decided whether to fill the vacancies.
Douglas Beck became chief financial officer and treasurer effective July 15, 2026, and serves as principal financial and accounting officer. He is a licensed certified public accountant.
Four directors were elected effective July 1, 2026, George Hornig became executive chairman and Terrence M. Tierney became interim chief executive officer. The annual evergreen increase falls from 10% to 3%.
Polomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license.
A May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month.
Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy in Palm Harbor, Florida. The pharmacy is also licensed as a Special Sterile Compounding Pharmacy and operates under Sec. 503A of the Federal Food, Drug and Cosmetic Act, which allows it to compound drugs for prescriptions from state licensed physicians and other licensed healthcare professionals. The company is licensed to fulfill and deliver compounded prescribed medications in 28 states and is seeking authorization in other states. Before its September 30, 2024 merger with the pharmacy, the business concentrated on compounded dermatological prescription medications for topical delivery, used for conditions such as acne, alopecia areata, basal cell carcinoma, Becker's nevus and vitiligo. The pharmacy has also fulfilled a limited number of prescriptions for sterile compounded GLP-1 agonists for subcutaneous injection. Under a one-year non-exclusive pharmacy services agreement signed September 26, 2025, it fulfills GLP-1 agonist prescriptions for the network of on-line clinics operated by CareValidate, Inc. The company describes itself as a development stage company with a limited operating history and reports significant losses from operations.
| Product or program | What it is | Stage |
|---|---|---|
| Polomar Pharmacy compounding | Retail and sterile compounding pharmacy filling prescriptions in 28 states | Licensed in 28 states |
| Dermatological compounded formulations | Topical compounded medications for acne, alopecia areata, vitiligo and other skin conditions | |
| Sterile compounded GLP-1 agonists | Sterile compounded GLP-1 agonists for subcutaneous injection | Fulfilled on a limited basis |
| CareValidate pharmacy services | Fulfills GLP-1 agonist prescriptions for an online clinic network | Fulfilling since October 6, 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $648,231 | $58,824 |
| Net income (loss) | -$10.7 million | -$1.3 million |
| Cash from operations | -$395,995 | -$1.0 million |
| Cash and equivalents | $132,150 | $6,191 |
Our latest story on this, dated Jun 15, 2026: "Polomar Health ends its Altanine merger and a patent license". The story links the filing or release it is based on. Read the story.
Polomar Health Services, Inc. trades under the ticker PMHS on OTC.
Polomar Health Services, Inc. is listed on OTC.
Our directory records Polomar Health Services, Inc. under United States.
aibio.space lists Polomar Health Services, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy in Palm Harbor, Florida. The pharmacy is also licensed as a Special Sterile Compounding Pharmacy and operates under Sec.
Polomar Pharmacy compounding: Retail and sterile compounding pharmacy filling prescriptions in 28 states Stage: Licensed in 28 states.
Dermatological compounded formulations: Topical compounded medications for acne, alopecia areata, vitiligo and other skin conditions Stage: Not stated.
$648,231 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Polomar Health Services, Inc. reported a net loss of $10.7 million for the fiscal year ended Dec 31, 2025, and used $395,995 of cash in operations, per its annual report to the SEC.
$87,818 in cash at Mar 31, 2026, per its 10-Q.
Our latest story on Polomar Health Services, dated Oct 19, 2026: "Two Polomar Health directors resign, leaving three on the board". Alexandra Peterson and Gabrielle Toledano resigned effective October 14, 2026, and the board reduced its size from five to three. The board has not decided whether to fill the vacancies. Source.
Our latest distress story, dated Jun 15, 2026: "Polomar Health ends its Altanine merger and a patent license". Polomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license. Source.
Press Follow on this page to add Polomar Health Services to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming Polomar Health Services so far, in Company Updates, Distress.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio